Skip to main content
SpringerLink
Log in
Book cover

Primary Sclerosing Cholangitis pp 1–11Cite as

Epidemiology and Natural History of Primary Sclerosing Cholangitis

  • Chapter
  • First Online:

Abstract

Primary sclerosing cholangitis (PSC) is defined as a disease of the medium and large bile ducts in which inflammation leads to segmental, concentric fibrosis with dilation of the more proximal portion of the bile duct. The diagnosis is typically made in the setting of inflammatory bowel disease with a cholangiogram demonstrating the classic beading of intrahepatic and/or extrahepatic ducts. PSC has been best studied in Northern European populations, most notably in Scandinavia where the prevalence appears to be the highest. Although estimates of the incidence of PSC have been increasing over time, it remains unclear if this is a true increase in incidence or a result of increased awareness and imaging leading to an increase in diagnosis. The natural history of PSC is extremely variable but frequently is one of the progressive fibrosis leading to biliary cirrhosis and ultimately liver failure or liver transplantation. Complicating the natural history are risks for cholangiocarcinoma, gallbladder cancer, and colon cancer as well as bacterial cholangitis and hepatic osteodystrophy. Several subgroups of PSC have been identified, and in whom the natural history of the disease varies. Understanding the natural history of PSC and the development of surrogate markers for clinically meaningful outcomes is critical to the evaluation of therapies in clinical trials.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Bjornsson E, Olsson R, Bergquist A, Lindgren S, Braden B, Chapman RW, et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology. 2008;134(4):975–80.

    Article  PubMed  Google Scholar 

  2. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology (Baltimore, Md). 2010;51(2):660–78.

    Article  CAS  Google Scholar 

  3. Dave M, Elmunzer BJ, Dwamena BA, Higgins PD. Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. Radiology. 2010;256(2):387–96.

    Article  PubMed  Google Scholar 

  4. Hekimoglu K, Ustundag Y, Dusak A, Erdem Z, Karademir B, Aydemir S, et al. MRCP vs. ERCP in the evaluation of biliary pathologies: review of current literature. J Dig Dis. 2008;9(3):162–9.

    Article  PubMed  Google Scholar 

  5. Weber C, Kuhlencordt R, Grotelueschen R, Wedegaertner U, Ang TL, Adam G, et al. Magnetic resonance cholangiopancreatography in the diagnosis of primary sclerosing cholangitis. Endoscopy. 2008;40(9):739–45.

    Article  CAS  PubMed  Google Scholar 

  6. Bambha K, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneau TM, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology. 2003;125(5):1364–9.

    Article  PubMed  Google Scholar 

  7. Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology. 2013;145(3):521–36.

    Article  CAS  PubMed  Google Scholar 

  8. Lindkvist B, Benito de Valle M, Gullberg B, Bjornsson E. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology (Baltimore, Md). 2010;52(2):571–7.

    Article  Google Scholar 

  9. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol. 1998;33(1):99–103.

    Article  CAS  PubMed  Google Scholar 

  10. Kingham JG, Kochar N, Gravenor MB. Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology. 2004;126(7):1929–30.

    Article  PubMed  Google Scholar 

  11. Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol. 2007;102(5):1042–9.

    Article  PubMed  Google Scholar 

  12. Boonstra K, Weersma RK, van Erpecum KJ, Rauws EA, Spanier BW, Poen AC, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology (Baltimore, Md). 2013;58(6):2045–55.

    Article  CAS  Google Scholar 

  13. Card TR, Solaymani-Dodaran M, West J. Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study. J Hepatol. 2008;48(6):939–44.

    Article  PubMed  Google Scholar 

  14. Toy E, Balasubramanian S, Selmi C, Li CS, Bowlus CL. The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population. BMC Gastroenterol. 2011;11:83.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Escorsell A, Pares A, Rodes J, Solis-Herruzo JA, Miras M, de la Morena E. Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. J Hepatol. 1994;21(5):787–91.

    Article  CAS  PubMed  Google Scholar 

  16. Tanaka A, Takikawa H. Geoepidemiology of primary sclerosing cholangitis: a critical review. J Autoimmun. 2013;46:35–40.

    Article  CAS  PubMed  Google Scholar 

  17. Hurlburt KJ, McMahon BJ, Deubner H, Hsu-Trawinski B, Williams JL, Kowdley KV. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol. 2002;97(9):2402–7.

    Article  PubMed  Google Scholar 

  18. Bowlus CL, Li CS, Karlsen TH, Lie BA, Selmi C. Primary sclerosing cholangitis in genetically diverse populations listed for liver transplantation: unique clinical and human leukocyte antigen associations. Liver Transpl. 2010;16(11):1324–30.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut. 1996;38(4):610–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Ponsioen CY, Vrouenraets SM, Prawirodirdjo W, Rajaram R, Rauws EA, Mulder CJ, et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut. 2002;51(4):562–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Angulo P, Maor-Kendler Y, Lindor KD. Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology (Baltimore, Md). 2002;35(6):1494–500.

    Article  Google Scholar 

  22. Kim WR, Poterucha JJ, Wiesner RH, LaRusso NF, Lindor KD, Petz J, et al. The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology (Baltimore, Md). 1999;29(6):1643–8.

    Article  CAS  Google Scholar 

  23. Kim WR, Therneau TM, Wiesner RH, Poterucha JJ, Benson JT, Malinchoc M, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clinic Proc Mayo Clinic. 2000;75(7):688–94.

    Article  CAS  Google Scholar 

  24. Corpechot C, Gaouar F, El Naggar A, Kemgang A, Wendum D, Poupon R, et al. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis. Gastroenterology. 2014;146(4):970–9; quiz e15–6.

    Article  PubMed  Google Scholar 

  25. Vesterhus M, Hov JR, Holm A, Schrumpf E, Nygard S, Godang K, et al. Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. Md).: Hepatology (Baltimore; 2015.

    Google Scholar 

  26. Bjornsson E, Lindqvist-Ottosson J, Asztely M, Olsson R. Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2004;99(3):502–8.

    Article  PubMed  Google Scholar 

  27. Rudolph G, Gotthardt D, Kloters-Plachky P, Kulaksiz H, Rost D, Stiehl A. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. J Hepatol. 2009;51(1):149–55.

    Article  PubMed  Google Scholar 

  28. Eaton JE, Juran BD, Atkinson EJ, Schlicht EM, Xie X, de Andrade M, et al. A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41(10):980–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Ngu JH, Gearry RB, Wright AJ, Stedman CA. Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2011;9(12):1092–7; quiz e135.

    Google Scholar 

  30. Halliday JS, Djordjevic J, Lust M, Culver EL, Braden B, Travis SP, et al. A unique clinical phenotype of primary sclerosing cholangitis associated with Crohn's disease. J Crohns Colitis. 2012;6(2):174–81.

    Article  CAS  PubMed  Google Scholar 

  31. Fevery J, Van Steenbergen W, Van Pelt J, Laleman W, Hoffman I, Geboes K, et al. Patients with large-duct primary sclerosing cholangitis and Crohn's disease have a better outcome than those with ulcerative colitis, or without IBD. Aliment Pharmacol Ther. 2016;43(5):612–20.

    Article  CAS  PubMed  Google Scholar 

  32. Abdalian R, Dhar P, Jhaveri K, Haider M, Guindi M, Heathcote EJ. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology. 2008;47(3):949–57.

    Article  CAS  PubMed  Google Scholar 

  33. Lewin M, Vilgrain V, Ozenne V, Lemoine M, Wendum D, Paradis V, et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study. Hepatology. 2009;50(2):528–37.

    Article  PubMed  Google Scholar 

  34. Mendes FD, Jorgensen R, Keach J, Katzmann JA, Smyrk T, Donlinger J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2006;101(9):2070–5.

    Article  CAS  PubMed  Google Scholar 

  35. Benito de Valle M, Muller T, Bjornsson E, Otten M, Volkmann M, Guckelberger O, et al. The impact of elevated serum IgG4 levels in patients with primary sclerosing cholangitis. Digest Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2014;46(10):903–8.

    Article  CAS  Google Scholar 

  36. Stanich PP, Bjornsson E, Gossard AA, Enders F, Jorgensen R, Lindor KD. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Digest Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2011;43(4):309–13.

    Article  CAS  Google Scholar 

  37. Lindstrom L, Hultcrantz R, Boberg KM, Friis-Liby I, Bergquist A. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2013;11(7):841–6.

    Google Scholar 

  38. Talwalkar JA, Chapman RW. The resurgence of serum alkaline phosphatase as a surrogate biomarker for prognosis in primary sclerosing cholangitis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2013;11(7):847–9.

    CAS  Google Scholar 

  39. Hilscher M, Enders FB, Carey EJ, Lindor KD, Tabibian JH. Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis. Ann Hepatol. 2016;15(2):246–53.

    PubMed  Google Scholar 

  40. Rustagi T, Dasanu CA. Risk factors for gallbladder cancer and cholangiocarcinoma: similarities, differences and updates. J Gastrointest Cancer. 2012;43(2):137–47.

    Article  CAS  PubMed  Google Scholar 

  41. Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol. 2009;50(1):158–64.

    Article  PubMed  Google Scholar 

  42. Fevery J, Henckaerts L, Van Oirbeek R, Vermeire S, Rutgeerts P, Nevens F, et al. Malignancies and mortality in 200 patients with primary sclerosering cholangitis: a long-term single-centre study. Liver Int. 2012;32(2):214–22.

    Article  PubMed  Google Scholar 

  43. Thackeray EW, Charatcharoenwitthaya P, Elfaki D, Sinakos E, Lindor KD. Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2011;9(1):52–6.

    Google Scholar 

  44. Ananthakrishnan AN, Cagan A, Gainer VS, Cheng SC, Cai T, Szolovits P, et al. Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease. J Crohns Colitis. 2014;8(9):956–63.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Bowlus CL, Olson KA, Gershwin ME. Evaluation of indeterminate biliary strictures. Nat Rev Gastroenterol Hepatol. 2016;13(1):28–37.

    Article  CAS  PubMed  Google Scholar 

  46. Goldberg DS, Camp A, Martinez-Camacho A, Forman L, Fortune B, Reddy KR. Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis. Liver Transpl. 2013;19(3):250–8.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Angulo P, Grandison GA, Fong DG, Keach JC, Lindor KD, Bjornsson E, et al. Bone disease in patients with primary sclerosing cholangitis. Gastroenterology. 2011;140(1):180–8.

    Article  PubMed  Google Scholar 

  48. Lebovics E, Palmer M, Woo J, Schaffner F. Outcome of primary sclerosing cholangitis. Analysis of long-term observation of 38 patients. Arch Intern Med. 1987;147(4):729–31.

    Article  CAS  PubMed  Google Scholar 

  49. Aadland E, Schrumpf E, Fausa O, Elgjo K, Heilo A, Aakhus T, et al. Primary sclerosing cholangitis: a long-term follow-up study. Scand J Gastroenterol. 1987;22(6):655–64.

    Article  CAS  PubMed  Google Scholar 

  50. Wiesner RH, Grambsch PM, Dickson ER, Ludwig J, MacCarty RL, Hunter EB, et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology (Baltimore, Md). 1989;10(4):430–6.

    Article  CAS  Google Scholar 

  51. Jeffrey GP, Reed WD, Laurence BH, Shilkin KB. Primary sclerosing cholangitis: clinical and immunopathological review of 21 cases. J Gastroenterol Hepatol. 1990;5(2):135–40.

    Article  CAS  PubMed  Google Scholar 

  52. Farrant JM, Hayllar KM, Wilkinson ML, Karani J, Portmann BC, Westaby D, et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology. 1991;100(6):1710–7.

    CAS  PubMed  Google Scholar 

  53. Tischendorf JJ, Hecker H, Kruger M, Manns MP, Meier PN. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol. 2007;102(1):107–14.

    Article  PubMed  Google Scholar 

  54. Tanaka A, Takamori Y, Toda G, Ohnishi S, Takikawa H. Outcome and prognostic factors of 391 Japanese patients with primary sclerosing cholangitis. Liver Int. 2008;28(7):983–9.

    Article  CAS  PubMed  Google Scholar 

  55. Yanai H, Matalon S, Rosenblatt A, Awadie H, Berdichevski T, Snir Y, et al. Prognosis of primary sclerosing cholangitis in Israel is independent of coexisting inflammatory Bowel disease. J Crohns Colitis. 2015;9(2):177–84.

    Article  PubMed  Google Scholar 

  56. Boberg KM, Rocca G, Egeland T, Bergquist A, Broome U, Caballeria L, et al. Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis. Hepatology (Baltimore, Md). 2002;35(3):652–7.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, University of California Davis, 4150 V Street, PSSB 3500, Sacramento, CA, 95817, USA

    Christopher L. Bowlus MD

Authors
  1. Christopher L. Bowlus MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher L. Bowlus MD .

Editor information

Editors and Affiliations

  1. Department of Gastroenterology-Hepatology, University of Colorado, Aurora, Colorado, USA

    Lisa M. Forman

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Bowlus, C.L. (2017). Epidemiology and Natural History of Primary Sclerosing Cholangitis. In: Forman, L. (eds) Primary Sclerosing Cholangitis. Springer, Cham. https://doi.org/10.1007/978-3-319-40908-5_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-40908-5_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-40906-1

  • Online ISBN: 978-3-319-40908-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation